On March 19, 2018, the 14th of 18 participants completed their 12-month long-term follow-up interview in our ongoing Marin, Calif., study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness. On March 9 and 12, 2018, Clinical Operations Manager Rebecca Matthews and Clinical Research Associate Alia Lilienstein of MAPS Public Benefit Corporation completed monitoring visits. Led by Principal Investigator Phil Wolfson, M.D., with Co-Therapist Julane Andries, L.M.F.T., this study is gathering preliminary data about the safety and efficacy of MDMA-assisted psychotherapy for anxiety associated with a diagnosis of a life-threatening illness. This study will close in May 2018. Learn more…